Breast cancer risk in relation to the interval between menopause and starting hormone therapy.
J Natl Cancer Inst 103(4):296-305 (2011) PMID 21278356
Although breast cancer risk is greater in users of estrogen-progestin than estrogen-only formulations of menopausal hormonal therapy, reports on their effects have been somewhat inconsistent. We investigated whether the timing of these therapies affected breast cancer incidence.
DOI: 10.1093/jnci/djq527
Version: za2963e q8za1 q8zb5 q8zc4 q8zdc q8ze7 q8zfb q8zg0